A Phase I/IIa Study to Assess the Safety, Tolerability, Biodistribution and Pharmacodynamic of T3011 Herpes Virus Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors.
Latest Information Update: 22 Mar 2024
At a glance
- Drugs T 3011 (Primary)
- Indications Advanced breast cancer; Breast cancer; Cancer metastases; Head and neck cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Sarcoma; Skin cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Immvira Pharma
- 15 Mar 2024 According to an Immvira Pharma media release, company announced that the U.S. Food and Drug Administration has granted Fast Track designation for MVR-T3011 IT (intratumoral injection) for the treatment of recurrent or metastatic head and neck squamous cell cancer with disease progression after platinum-based chemotherapy and at least one prior line of anti-PD1/PDL1 therapy. Supporting evidence for this request was derived from Phase I/II trials conducted in both the United States and China.
- 06 Jun 2023 Results (As of 18 Jan. 2023, n=90) assessing safety and efficacy of T3011 in advanced solid tumorspresented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 According to a ImmVira pharma media release, the company presented results from Phase I/II clinical trials of MVR-T3011 IT (intratumoral injection) in China with all selected to be published (1 chosen for poster discussion) at the 2023 American Society for Clinical Oncology Annual Meeting (ASCO 2023)